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The melanocortin-4 receptor (MC4R) can be endogenously activated by binding
of melanocyte-stimulating hormones (MSH), which mediates anorexigenic effects. In
contrast, the agouti-related peptide (AgRP) acts as an endogenous inverse agonist and
suppresses ligand-independent basal signaling activity (orexigenic effects). Binding of
ligands to MC4R leads to the activation of different G-protein subtypes or arrestin and
concomitant signaling pathways. This receptor is a key protein in the hypothalamic
regulation of food intake and energy expenditure and naturally-occurring inactivating
MC4R variants are the most frequent cause of monogenic obesity. In general, obesity
is a growing problem on a global scale and is of social, medical, and economic
relevance. A significant goal is to develop optimized pharmacological tools targeting
MC4R without adverse effects. To date, this has not been achieved because of inter
alia non-selective ligands across the five functionally different MCR subtypes (MC1-5R).
This motivates further investigation of (i) the three-dimensional MC4R structure, (ii)
binding mechanisms of various ligands, and (iii) the molecular transfer process of
signal transduction, with the aim of understanding how structural features are linked
with functional-physiological aspects. Unfortunately, experimentally elucidated structural
information is not yet available for the MC receptors, a group of class A G-protein coupled
receptors (GPCRs). We, therefore, generated MC4R homology models and complexes
with interacting partners to describe approximate structural properties associated with
signaling mechanisms. In addition, molecular insights from pathogenic mutations were
incorporated to discriminate more precisely their individual malfunction of the signal
transfer mechanism.
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INTRODUCTION
The melanocyte-stimulating hormones (α-, β-, γ-MSH) and the
adrenocorticotropic hormone (ACTH) are agonistic peptidic
ligands that bind to a group of five class A GPCRs (1),
namely the melanocortin-receptors 1–5 (MC1-5R). In contrast,
the endogenous melanocortin receptor antagonist AgRP (2–4)
inhibits basal constitutive signaling (5) as a potential inverse
agonist and simultaneously preventsMSH binding. These ligands
and receptors are involved in regulating various physiological
functions, such as skin pigmentation, energy homeostasis,
erythrocyte differentiation, thermal homeostasis, appetite, and
adrenal, or sexual function (6–9). MCRs are expressed in many
tissues and mutations in MCRs cause pathogenic conditions
such as analgesia, obesity, hypocortisolism, and inflammation
(4, 10). The MC2R, in contrast to other MCRs, is specific
because it is activated only by ACTH and requires an interplay
with the melanocortin receptor accessory protein (MRAP) to
attain functional expression (11). MC2R activation is associated
with stress responses by promoting the synthesis and secretion
of adrenal glucocorticoids along the hypothalamic-pituitary-
adrenal axis (12).
The MC4R has a fundamental role in regulating food intake
and energy expenditure (13, 14). It is expressed primarily in the
hypothalamic paraventricular nucleus, spinal cord, sympathetic
preganglionic neurons, and brainstem (15, 16). MC4R mainly
couples to the G-protein Gs (17) as a cAMP-dependent pathway
activator, but can also activate other G-protein subtypes such
as Gq or Gi (18, 19). Agonist-mediated and basal (constitutive)
MC4R signaling activity was proposed to differentially impact
various N-type voltage-gated calcium channels (CaV) through
Gs and Gi/o pathways. In addition, chronic incubation with
AgRP occludes CaV inhibition (20). Moreover, regulation of
neuronal firing activity from the paraventricular nucleus of the
hypothalamus (PVN) by α-MSH and AgRP can be mediated by
the inwardly rectifying potassium channel, Kir7.1 (21).
Agonistic action at MC4R induces an anorexigenic effect
(appetite reducing) (22) in contrast to the antagonistic ligand
AgRP with orexigenic effects (19). To date, inactivating MC4R
mutations (23) are the most frequent monogenic cause of
obesity (24). Currently, there are estimated to be more than
650 million adults with obesity worldwide (25). As obesity is
related to different comorbidities such as diabetes mellitus type
2 or cardiovascular disease (26), there is considerable medical,
pharmacological, as well as economic interest concerning this
receptor (27). The design of highly selective and potent MC4R
ligands (28, 29) should be a tool to counteract specifically against
obesity (9, 30), which also needs a comprehensive understanding
of this receptor under structural-functional perspectives.
In recent years, a large amount of information on the MC4R
was gained including the identification of the interacting and
signaling regulating melanocortin-2 receptor accessory protein
(MRAP2) (31, 32), a newly discovered endogenously acting
ligand lipocalin-2 (33), highly efficient synthetic, or peptidic
ligands such as setmelanotide [termed RM-493, previously BIM-
22493, IRC-022493] (23, 34–36), or bivalent ligands [e.g., (37–
41)]. In addition, this receptor constitutes protein oligomers that
are of functional importance (42–44) and few pathogenic MC4R
variants have been reported to be dominant-negative on wild-
type receptor function (42, 45). Finally, as already shown for
otherMCRs such as theMC1R andMC5R (46), heteromerization
has been demonstrated for MC4R, which is consequently a
further modulatory factor in the MC4R interaction network
(47, 48).
Interestingly, several pathogenic MC4R mutations have been
observed to cause biased signaling through the MC4R by
inducing a preference for a specific signaling pathway. Moreover,
AgRP can simultaneously induce or block different signaling
pathways and newly developed biased MC4R ligands were
applied as an anti-obesity treatment (19, 49, 50).
These insights indicate an elaborate and complex regulatory
mechanism of the MC4R on a molecular and cellular level, with
a multitude of interacting proteins, and (patho-) physiological
relationships (51). Unfortunately, structural information on the
MCR subtypes is not yet available, hampering our understanding
of this functional information. Therefore, in the present study, we
generated and used structural models of ligand/MC4R complexes
as well as a ligand/MC4R/G-protein ternary complex to evaluate
general and local features of signaling-related processes under the
perspective of structure-function relationships. Finally, this also
aids in improving our understanding of pathogenic mutations in
receptor activation at the molecular level.
METHODS
Modeling of the Human MC4R in an
Inactive State Conformation
The computational modeling procedure of the human
MC4R (hMC4R) in an inactive state conformation was
recently described in detail by our group (52). Briefly, the
lysophospholipid sphingosine 1-phosphate receptor structure
[S1PR1, PDB entry 3V2Y) (53)], which has a high sequence
similarity (∼50%) to hMC4R in the transmembrane region,
was used (Figure 1). Additionally, this template shows specific
overlapping features with the MC4R, e.g., S1PR1 is characterized
by a leucine in transmembrane helix (TMH) 5 position 5.50
[according to the Ballesteros & Weinstein numbering system
(55)] and consequently has a regular α-helical conformation,
which is expected for the MC4R due to the presence of
methionine at the corresponding position (Figure 1). In most
other class A GPCRs, TMH5 is kinked due to the location of
proline at position 5.50.
The disulfide bridge between extracellular loop (ECL) 2 and
transmembrane helix (TMH) 3 is missing in S1PR1 and is also
assumed for the MC4R (absence of cysteine at the respective
positions). A disulfide bridge is present in ECL3 and also
proposed for the MC4R (57).
The N-terminus of S1PR1 comprises 40 amino acids
compared to 39 amino acids in hMC4R. Template preparation
included loop length adjustments. Missing residues between the
N-terminal helix and TMH1 (between A39–L47) were added
manually. Amino acids in the S1PR1 template were substituted
with residues of the hMC4R according to the sequence alignment
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FIGURE 1 | Amino acid sequence alignment between MCR subtypes and potential structural templates for MC4R homology modeling in different activity states. The
sequence alignment shows overlapping or diverse properties between the five MCR subtypes, the sphingosine 1-phosphate receptor 1 [S1PR1, template for inactive
state MC4R homology models, PDB entry 3V2Y (53)], the prototypical class A rhodopsin, and the β-adrenergic receptor [ADRB2, template for active state MC4R
homology model, PDB entry 3SN6, (54)]. Highly conserved positions according to the Ballesteros and Weinstein numbering scheme (55) are indicated by respective
numbers. The very short ECL2 of the MCR group compared to other GPCRs is highlighted by a light blue rectangle. Predicted structural dimensions of each receptor
segment are indicated above the sequences. The alignment was visualized using the software BioEdit (56). Specific background colors indicating conservation
(Blossum62 matrix) among different receptors and reflecting chemical properties of the amino acid side-chains: black, proline; blue, positively charged; cyan/green,
aromatic and hydrophobic; green, hydrophobic; red, negatively charged; gray, hydrophilic; dark red, cysteines; and magenta, histidine.
between S1PR1 and hMC4R (Figure 1), followed by energy
minimization of side chains. This preliminary model was
refined by molecular dynamic simulations of side chains and
loops, succeeded by energy minimization until converging at
a termination gradient of 0.05 kcal/mol∗Å. The AMBER (58)
F99 force field was used for energy minimization and dynamic
simulations included in Sybyl X2.0 (Certara, NJ, US).
Ligand Models
While many MCR ligands, synthetic or endogenous, are already
known (59, 60), we here focused only on a small subset of
endogenous native ligands such as alpha-MSH or AgRP to link
structural models with the different aspects of MC4R signaling
and regulation. We recently described a modeling and docking
procedure for the hMC4R in a complex with the agonistic peptide
ligands α-MSH and setmelanotide (50). The MC4R/α-MSH
complex model was used to compare the suggested bindingmode
with the here inferred binding mode between hMC4R and AgRP,
zfMC4RwithMSH, but also to visualize putativeMC4R oligomer
arrangements and to map amino acid positions of pathogenic
mutants. For AgRP, a previously determined structure of a
functionally active protein fragment is available [PDB entry
1HYK (61)] with amino acids between the positions 87–132. Of
note, further information on peptidic ligand structures has been
published previously (62).
Ligand/Receptor Complex-Assembling
For ligand docking of AgRP into the inactive MC4R model (see
section Ligandmodels) the known structural AgRP fragment (see
section Ligand models) was placed manually in the extracellular
solvent phase at approximately 5 Å separation from the hMC4R
surface in close spatial proximity above the extracellular loops. A
known interaction between the amino acids of the ligand and the
receptor involved in binding (16, 63–66) was used as a distance
constraint. In particular, the specific AgRP motif 111RFFN114 is
essential for interaction with the orthosteric site of the MC4R
and the MC3R (67, 68). In accordance to others [reviewed
in Ericson et al. (9)], we thereby assumed that the positively
charged side chain of R111 (AgRP) interacts with the negatively
charged side chains of D122 and D126 (MC4R). Molecular
dynamic simulations (300K, 3 ns) were initiated with a distant
constraint of 2 Å between the side chains of AgRP R111 and
hMC4RD126. All backbone atoms of the receptor helices and the
ligand were constrained. The resulting model was energetically
minimized, followed by a second dynamic simulation (2 ns)
without any distance constraints on the ligand backbone. The




Our recently described hMC4R/α-MSH complex model (50),
based on the determined active state β-adrenergic receptor
(ADRB2) structure as a complex with heterotrimeric Gs [PDB
entry 3SN6 (54)], was superimposed with the initial receptor/Gs
complex template. The heterotrimeric G-protein from the
template was substituted into the MC4R/ligand complex model.
Dynamic simulations (300K, 2 ns) of the side chains and loop
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structures were used to optimize interactions and intramolecular
distances in the complex, whereby the backbone atoms of the
receptor helices were constrained. The resulting model was
energetically minimized without any structural constraint.
Homology Modeling of Complexes
Between Zebrafish MC2R or zfMC4R and
Agonistic Peptide Ligands
Our recently published hMC4R homology as a complex with α-
MSH (50) was used as a template for modeling the zebrafish
(zf) MC4R as a complex with α-MSH, but also for the zfMC2R
bound with agonistic ACTH. The purpose was to evaluate the
possibility of similar ligand binding modes at these receptors on
a structural level and to suppose a potential mechanism of action
for ACTH at zfMC2R. This can be reasoned by the identification
of two MRAP paralogue genes in zebrafish, zfMRAP2a, and
zfMRAP2b (69), with zfMRAP2a found to increase the zfMC4R
response to ACTH, most likely by heteromerization [Josep et al.
(70)]. Consequently, zfMC4R becomes an ACTH receptor in
the presence of MRAP2a and similar results have been reported
recently in chickens (60) and also for the human MC4R (71) in
interaction with MRAP2. Therefore, our complex models should
help to generate functional mechanistic hypotheses concerning
increased ACTH sensitivity at zfMC4R mediated by interaction
with MRAP2a, although we cannot offer a concrete heteromeric
MC4R/MRAP2 complex model because of missing structural
information on MRAP (no valuable template or elucidated
structure is available).
The overall sequence identity between zfMC4R and hMC4R
(Supplementary Figure 1) is 68%, whereas the sequence
similarity between zfMC4R and zfMC2R is∼60% (the Blossum62
matrix was applied). The hMC4R model was used as a template
and the zfMC4R amino acids were substituted into this template,
followed by energy minimization of side chains. The modeling
and docking procedure of α-MSH to hMC4R was previously
described by our group (50), with the identical procedure used
to dock α-MSH into the zfMC4R.
Structural modifications to adapt the hMC4R model toward
a three-dimensional zfMC2R structure (e.g., deletion of amino
acids in the N-terminus (Ntt) and concomitant amino acid
sequence substitutions) were performed using the software
Sybyl X2.0 (Certara, NJ, US). Moreover, ACTH has an N-
terminal sequence that is identical with α-MSH, but the
consecutive residues of the extended ACTH are reported to
act antagonistically at MC2R as a single peptide (51). Because
the structure of ACTH has not yet been determined, the MSH
model was used as a template (positions 1–12) and functionally
relevant amino acids were added manually from positions 13–
24. The essential amino acids covering the binding site of
MSH are conserved between hMC4R, zfMC4R, and zfMC2R
(Supplementary Figure 1). Therefore, the hormone model was
placed into the zfMC2R model with the “MSH-moiety” as
supposed from the zfMC4R/MSH complex. The conformation
and binding mode of ACTH in zfMC2R were adapted during 1
ns molecular dynamics of the complex [Amber force field (58)]
with fixed backbone atoms of receptor helices and of ligand
amino acids 1–12. The entire model-complex was energetically
minimized without constraint.
Dimeric and Oligomeric MC4R Complexes
The MC4R has the capacity to constitute homodimers (42–44).
Functional data based on particular MC4R constructs suggest
that specific parts of TMH3, intracellular loop 2 (ICL2), and
TMH4 (TMH3- ICL2-TMH4) are involved in the interface
between the receptor protomers (72). MC4R homodimerization
is of functional importance with regard to signaling capacity
(72). Based on previously determined crystal structures of
class A GPCR dimers [reviewed in Audet and Bouvier (73)]
as well as considerable biophysical studies, several oligomeric
GPCR protomer arrangements were previously suggested (details
described below). Consequently, dimeric GPCR constellations
with different protomer interfaces can be predicted for GPCR
dimers in the absence of structural information andGPCR crystal
structures are useful to serve as templates for dimeric GPCR
homology models [reviewed in Audet and Bouvier (73)].
Two putative oligomeric MC4R models were generated by
superimposition of protomers (MC4R/α-MSH complex) with
structural templates representing the two most commonly
observed dimer arrangements [reviewed in Katritch et al. (74)
and Baltoumas et al. (75)]. First, an MC4R homodimer with an
interface between parts of TMH4, ICL2, and TMH5, based on
the dimeric crystal structure of C-X-C chemokine receptor type
4 (CXCR4), was constructed. Second, an MC4R dimer model
based on the human κ-opioid receptor (KOR) crystal structure
was designed. These two differentMC4R-MC4R dimeric complex
models were sterically and energetically optimized using dynamic
simulations (1 ns) of the side chains and loop structures,
whereby the backbone atoms of the receptor helices were
constrained. The resulting model was energetically minimized
without structural constraint.
RESULTS AND DISCUSSION
The Putative Three-Dimensional MC4R
Protein Structure
TheMC4R is constituted by structural features typical for GPCRs
such as seven transmembrane spanning helices connected by
intra- and extracellular loops, an extracellular N-terminus, and
an intracellular C-terminal tail (76). Highly conserved amino
acids at each helix (Figure 1) are related to common structural
properties such as kinks and bulges, or essential intramolecular
interactions that are significant for an intrinsically encoded
signal transduction competence. However, the MC4R is also
characterized by specific putative structural features related to
specific amino acid sequence properties. For example, the ECL2
is extremely short with around four amino acids and the highly
conserved disulfide bridge among GPCRs between the ECL2
and TMH3 is missing (Figures 1, 2). Moreover, the MC4R is
characterized by a regular α-helical conformation of TMH5
because of a methionine instead of a proline (P5.50) that is
highly conserved in class A GPCRs and induces a helical kink
and bulge. This property is of enormous impact because the
orientation of side chains in TMH5 toward the membrane or
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FIGURE 2 | MC4R homology model in a putative inactive state. The
three-dimensional hMC4R model (protein backbone as a cartoon) represents
predicted general and specific structural features. First, the TMH5 in most
class A GPCRs is characterized by a bulge and kink caused by occurrence of
a highly conserved proline (P5.50); however, in the MCRs, there is a methionine
instead of a proline at this position (Figure 1). This suggests a regular α-helical
conformation (light magenta) for TMH5 as also observed in the structural
template for the inactive state modeling [S1PR1, PDB entry 3V2Y (53)].
Second, the ECL2 (red) of all MCRs is extremely short in length compared to
other GPCRs. Moreover, the highly conserved disulfide bridge in GPCRs
between two cysteines located in ECL2 and the TMH3 is absent because of
missing cysteines at respective positions. In the ECL3, two cysteines constitute
a disulfide bridge (57). The N-termini of MCRs do not demonstrate overlapping
in the sequence comparison (Figure 1); however, there has been discussion
on the involvement of a specific N-terminal region in signaling regulation in the
MC4R (77, 78). Finally, the conserved NPxxY motif in the TMH7 is a DPxxY
motif with different chemical properties for this microdomain in the MC4R.
the transmembrane core depends on this helical feature, which
affects properties of the ligand-binding region between the helical
core and the extracellular loops (Figures 3, 4).
The highly conserved class A GPCR amino acid motif
7.49NPxxY in TMH7 is a 7.49DPxxY motif in the MC4R. To
date, approximately 20% of ∼300 class A GPCRs (with the
exception of olfactory class A GPCRs) are characterized by
an aspartate at position 7.49 instead of an asparagine (72%).
This sequence variation is not rare, whereby it is not yet
clearly defined which structural and functional consequences
this evolutionary modification can be attributed to Katritch
et al. (79). Based on several mutagenesis and signaling studies
in diverse GPCRs [e.g., (80)] or determined structures (81),
an aspartate at position 7.49 (negatively charged side chain)
has been discussed as potentially contributing to the binding
of positively charged sodium ions (increased binding, different
spatial coordination) in an interaction network with water
molecules and the highly conserved aspartate D2.50 in helix 2
(and other residues of the potential sodium binding site) (45).
This suggestion is also supported by the previously determined
crystal structure of human protease-activated receptor 1 (PAR1)
(82), which includes aspartate at this position. In P2Y12, another
class A GPCR with a determined structure (83), endogenous
aspartate D7.49 was substituted with an asparagine to stabilize
the protein sample for crystallization. Of note, the PAR1 crystal
structure presents a sodium binding site that differs to other
crystallized GPCRs [e.g., in the high resolution structure of the
adenosine-receptor A2AR (84)], whereby the location of sodium
is differently adjusted between positions D2.50 and D7.49. The
PAR1 structure supposes that a negatively charged side chain
leads to closer interaction with the sodium ion toward D7.49 in
contrast to GPCRs with a non-charged asparagine side chain at
this position, with the sodium ion located between D2.50 and
N7.45 [reviewed in Katritch et al. (79)]. It was also speculated that
a double aspartate constellation (D2.50/D7.49), as observed in
all MCRs and in the P2Y12 orthologs (85), should bind divalent
cations instead of receptors with a more conserved D2.50/N7.49
variation. In addition, a D7.49 should alternatively support
binding of a sodium ion in GPCRs with an N2.50 [reviewed in
Katritch et al. (79)]; however, this cannot be the case for the
MC4R with a D2.50 (45).
For the hMC4R, previous mutagenesis studies showed a
fully hampered signaling capacity for the D298A (D7.49A)
substitution, supporting a fundamental role of this position in
receptor signaling (whereby ligand binding was not significantly
affected) (63). Interestingly, the endogenous D298N variant
in pig MC4R is controversially discussed to be involved in
weight gain [reviewed in Switonski et al. (86)]. A previous
comparison between the D7.49N variant in pig MC4R and
hMC4R have not pointed toward differences in resulting binding
or signaling capacities at both receptors and have not provided
any significant impact of this variant on ligand binding or cAMP
signaling. In summary, the MC4R and other MCRs exhibit a
significant variant in this conserved TMH7 motif, which may
impact the binding of ions in class A GPCRs. The sodium-
ion and surrounding water molecules are in tight hydrogen
bond interactions with surrounding hydrophilic amino acid side
chains and may impact signaling properties, including signaling
pathway preferences, TMH7 orientation, and receptor dynamics,
implying regulation of transitions between different receptor
activity states (79, 81). Of note, in all available active state GPCR
structures, a sodium ion is absent, which supports specifically a
role in the constitution of a signaling-competent conformation.
In conclusion, this feature of MC4R might be directly related
to signaling properties; however, the detailed mechanism or
concrete structural insights are still missing.
In addition, a supposed disulfide bridge in ECL3 (C271–C277,
Figure 1) was previously confirmed by mutagenesis studies (57).
This disulfide bridge is in accordance with findings at the MC2R
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FIGURE 3 | MC4R in interaction with native agonist α-MSH. (A) The human hMC4R/α-MSH complex model reveals that the peptide agonist binds into a cleft
between the extracellular loops and transmembrane helices. (B) More than twenty hMC4R amino acids (examples labeled) constituting the putative ligand binding
pocket (inner surface, clipped, green). In α-MSH, the central recognition motif 6HFRW9 is involved in mediating ligand induced effects.
FIGURE 4 | MC4R in interaction with the endogenous inverse agonist AgRP. The available solved structure (determined by NMR) of a functionally active AgRP peptide
[inverse agonist, PDB entry 1HYK (61)], with the amino acid residues 87–132, was docked into the putative inactive state model of MC4R (A). This peptide is
stabilized by several disulfide bridges and involved cysteines are represented as spheres. Ligand side-chains participating in receptor interactions are shown as sticks.
Of note, in the central active part of this ligand, a 111RFF113 motif is located deep in the receptor binding site, whereby arginine 111 is embedded between negatively
charged receptor amino acid residues, e.g., D122 and D126. Further significant interactions suggested by our model are (ligand/receptor): F112/F184, F113/F261,
F116/F284, Y118/Y35, Y109/Y268, and R120/D189. In (B), a surface representation of the agonist α-MSH visualizes the dimension and suggested general
localization of α-MSH in the MC4R model, with amino acids constituting the supposed binding site (side chains as green lines) covering the binding pocket. (C) The
surface representation of AgRP bound to MC4R shows, even a fragmental AgRP, the difference in bulkiness of AgRP compared to the agonistic α-MSH (C).
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(87). Moreover, a second extracellular disulfide bridge should
be postulated between a further cysteine in the ECL3 (C279)
and in the transition between the N-terminus and TMH1 (C40).
However, mutagenesis studies at these two cysteine residues
did not reveal a significant functional influence; therefore,
experimental evidence for this supposed disulfide bridge is not
yet available. Previous studies suggested that a fragment of the
N-terminus should be embedded between the transmembrane
helices and act as an intramolecular tethered (partial) agonist (77,
78). This interesting suggestion is not included in the putative
MC4R models in the present study, because most naturally-
occurring substitutions in the N-terminus region were not yet
found to be of functional significance (Supplementary Table 1),
which does not support a fundamental role of the N-terminus
in signaling regulation. Conservation of the MC4R N-terminus
among receptor orthologous is, however, high, even at the
HxWNRS motif (Supplementary Figure 2), which supposedly
interacts intermolecularly with amino acids in the helical bundle,
thereby contributing to the signaling capability of the receptor
(permanent basal activity). However, at this motif, several
species-specific variations can be observed, e.g., several fish
MC4Rs expose an xY/FRNHS motif, which deviates significantly
from the corresponding human MC4R N-terminus.
Based on molecular dynamic simulations, a recent study
reported the potential involvement of the N-terminus in the
stepwise binding of a small molecule (antagonist MCL0129) and
that ligand selectivity parameters are also potentially encrypted
in the N-terminus (52). Notably, the N-terminal sequence is not
conserved among the different MCR subtypes (Figure 1). Finally,
it can be supposed that the MC4R N-terminus can contribute
to receptor signaling properties; however, further experimental
studies are required.
Ligand Binding at the MC4R
The different MSH variants are agonistic peptide ligands that
bind to the MC4R. Moreover, the endogenous inverse agonist
AgRP inhibits basal constitutive signaling. The mechanism
of ligand binding and ligand selectivity are important aspects
required for gaining a comprehensive understanding of
this receptor from biological, medical, and pharmaceutical
perspectives. This is further complicated by the assumption
that several accompanying processes or factors contribute to
ligand binding, such as the oligomeric MC4R constellation
(88), or zinc ions (89). However, in regard also to developed
non-endogenous MC4R ligands (9, 29, 35), this issue requires
investigation. Therefore, in the following section, we briefly
present and discuss insights into ligand binding with particular
emphasis on structural aspects.
In our recent study, we presumed particular binding modes
of the agonistic peptides α-MSH (linear) and the cyclic
setmelanotide (also termed RM-493) at the MC4R (50). Briefly, a
high number of intermolecular contacts with the transmembrane
region (TMHs 2-7) as well as ECL2 and ECL3 determines the
mode of α-MSH binding, which is generally in accordance to
putative ligand/receptor contacts [reviewed in Ericson et al.
(9) and Tao (16)]. Proposed direct substantial contacts are,
for example (α-MSH/MC4R amino acid denotation), W9/F261;
R8/E100, D122, D126; F7/F184; and H6/Y268. In α-MSH and
other MC4R ligands (e.g., setmelanotide), the central recognition
motif 6HFRW9 (9) is located between the extracellular ends of
the transmembrane helices (Figure 3). However, in particular,
the N-terminal histidine of both ligands differs in its orientation.
The H4 in RM-493 is most likely located between TMH3 (N123)
and TMH4 (F184); however, in the α-MSH/MC4R complex, the
corresponding H6 is located between TMH6 (Y268) and TMH5
(S191). Finally, it can be postulated that both ligands share
specific interactions of the highly conserved ligand motif HFRW
with MC4R [see also (90)]. Yet, specific amino acids such as N-
terminal histidine residues differ in their detailed interactions
with side chains in MC4R (50), which is likely justified by the
different linear or cyclic structures of both agonists.
Based on kinetic ligand binding studies, two different
tandemly arranged and presumably interrelated ligand binding
sites in oligomeric MC4R complexes were suggested (88),
which are also associated and complementary to studies on
MC4R oligomers (42–44) (see chapter MC4R oligomerization—
putative protomer interfaces and contribution to signaling) and
bivalent ligand binding (presented below in detail) (37–41). In
addition, zinc ions can act agonistically and as positive allosteric
modulators in the MC4R (89).
These insights into agonistic or allosteric ligand binding
generate interest regarding differences in the binding of agonists
in comparison to the inverse agonistic ligand AgRP [for Gs-
mediated cAMP signaling, see (49)]. The available solved
structure of a functionally active AgRP peptide [PDB entry
1HYK (61)] was docked into the MC4R model (Figure 4).
In the central part of this ligand, a 111RFF113 motif is
located deep in the receptor, whereby R111 is surrounded by
the negatively charged, receptor amino acid residues E100,
D122, and D126. This presumable interaction corresponds to
experimental hints generated in different studies on AgRP
binding (63–66). Further significant interactions suggested by
our model are (AgRP/MC4R amino acid denotation) namely,
F112/F184, F113/F261, F116/F284, Y109/Y268, Y118/Y35, or
R120/D189. These potential ligand-receptor interactions are
likely AgRP-specific and not relevant for the binding of the
agonistic ligands MSH or setmelanotide (50). The AgRP contacts
are generally spread over diverse receptor parts, including
transmembrane helices, the extracellular loops, and the N-
terminus. This may help explain the antagonistic and, especially,
the inverse agonistic effects of AgRP, whereby these contacts
may function as constraints keeping the MC4R in a practically
inactive state conformation, at least for certain signaling
pathways (49).
Of note, the C-terminal sequence of AgRP is highly conserved
among different species and is characterized by a defined
patterned distribution of cysteine residues and disulfide bridges
(Supplementary Figure 3), while the N-terminal half is not
highly conserved among many orthologs [this structural part is
not included in the crystal structure [PDB entry 1HYK (61)].
AgRP is cleaved intracellularly by a convertase at position 83
(91). Accordingly, in our putative binding mode for AgRP at the
MC4R (Figure 4), the conserved region contributes exclusively to
intermolecular contacts.
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FIGURE 5 | Structural protein dimensions of MC4R and lipocalin-2. In a recent
study (33), lipocalin-2 (LCN2), a bone-derived hormone with metabolic
regulatory effects, was reported to bind to MC4R, thereby suppressing
appetite (anorexigenic effect). Without detailed experimental studies on the
binding mechanism between MC4R and the β-barrel folded lipocalin,
predictions on how this hormone interacts with the receptor cannot be made.
However, comparing the structural dimensions of the engineered lipocalin
variant Anticalin US7 [PDB entry 4MVI (92)] with our MC4R model (A, as a
ribbon presentation; B, as a surface representation) shows the huge hormone
protein that most likely interacts with the MC4R in a manner completely
different to other peptidic MC4R ligands (Figures 3–4).
A recent study reported that lipocalin-2, a bone-derived
protein, acts as an agonist at the MC4R, whereby lipocalin-2
crosses the blood-brain barrier and interacts with the MC4R
in the hypothalamus (33). The crystal structure of lipocalin-2
is shown in Figure 5. Additionally determined apo-lipocalin or
lipocalin-complex structures (e.g., PDB entries 1KXO, 1LKE, and
1N0S) should be used to estimate the putative binding sites of this
protein for interaction with the MC4R. As depicted in Figure 5,
only the spatial dimensions of both interacting proteins can
be visualized, reasoned by the yet absent functional-molecular
data concerning the putative lipocalin binding mechanism to
this receptor.
Interestingly, a previous study reported that zfMC4R shows
increased ACTH sensitivity mediated by the escort protein
MRAP2a (93). Similar results with MRAP2 were reported
recently for chicken (60) and for the human MC4R (71). Only
MC2R has been known to usually interact with ACTH with
high affinity. The question that arises is: how can this effect and
difference to other MCRs be explained? To obtain structural
insights into similarities or differences between zfMC4R/MSH
or zfMC2R/ACTH complexes, we designed zfMC4R-αMSH and
zfMC2R-ACTH models. These models may help to generate
hypotheses concerning the reported effect of MRAP2a in
interplay with zfMC4R, leading to increased ACTH-ligand
sensitivity (93).
First, highly essential residues involved in ligand binding at
the hMC4R are observed to also be conserved in zfMC4R, yet are
also located in corresponding positions of the zfMC2R (Figure 6,
Supplementary Figure 1). This circumstance helps to explain
why these two receptors are able to bind αMSH or the MSH
amino acid moiety of ACTH (Figure 6), in the case of zfMC4R
through MRAP2a participation, respectively. These important
amino acids for MSH binding include (hMC4R numbering):
E100, D122, D126, F261, H264, and F284 (Figure 6). This
conservation suggests that the binding mode, at least in the
central core of MSH (6HFRW9), is most likely comparable
between human and zebrafish MC4R and that the N-terminal
MSH-like moiety in ACTH is also bound to zfMC2R in a
similar binding mode as suggested for αMSH in the MC4Rs.
This is further supported by pathogenic findings, where an
essential amino acid of the N-terminal ACTH peptide (Arg8Cys)
is mutated, causing glucocorticoid deficiency by decreased
hormone binding (94). However, the difference between ACTH
and MSH binding at MCRs is likely associated with the
amino acids 13–24 of ACTH. They can interact with the
receptor at several structural parts external of the MSH binding
site, especially with the extracellular loops. These additional
interactions between ACTH and zfMC2R, e.g., with the ECL3
(Figure 6), may be responsible for the endogenous capacity of
MC2R to interact with ACTH. Finally, based on these models,
it can be postulated that MC4Rs and other MCRs might be
characterized by structural features, e.g., a longer N-terminus
compared to MC2R (Figure 1), that excludes or hinders steric
and/or biophysical ACTH binding. This would precipitate the
suggestion that MRAP2 interaction with MC4R must modify
specific structural features such as the N-terminus (see also
Supplementary Figure 1), which differs compared to MC2R
to enable high ACTH affinity binding. Detailed experimental
studies addressing this question have not yet been performed.
MC4R Oligomerization—Putative Protomer
Interfaces and Contribution to Signaling
The MC4R is known to constitute homodimers or homo-
oligomers (42–44). In addition, heteromericMC4R interrelations
with GPR7 (47) or MC3R (40) were reported recently. It
remains elusive how these oligomeric protein constellations, if
functionally relevant, are arranged and what their functional
consequences regarding receptor signaling properties are.
Generally, GPCR dimerization has been found to impact
physiological aspects (95–97) and pathophysiological conditions
(98–101). Oligomerization of GPCRs is known to potentially
influence ligand binding (102, 103), G-protein selectivity
(104), signal transduction mechanisms (105, 106), or cell
surface expression (107). Moreover, allosteric effects between
individual protomers were reported (108). Recently, forced
MC4R monomerization was revealed to cause almost twice
the maximum in cAMP-signaling compared to the MC4R
with the capacity to constitute oligomers (72). This leads to
the assumption that signaling properties of MC4R monomers
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FIGURE 6 | Structural insights into ligand binding at human and zebrafish MCR subtypes. (A) The human hMC4R/α-MSH complex model (inner clipped surface
representation of the binding pocket) assumes that the agonist (magenta) binds into a pocket-like cleft between the extracellular loops (EL) and the transmembrane
helices (TM). Specific conserved amino acids (Figure 3) covering the ligand binding pocket (green sticks). Importantly, in α-MSH and other MC4R ligands, a central
amino acid motif 6HFRW9 is essentially involved in ligand recognition and induction of ligand effects (9). (B) This agonistic motif is likely located between the helices
also in the zfMC4R and interacts with the conserved amino acids among MCRs. Consequently, we assume comparable MSH binding modes in hMC4R and zfMC4R.
(C,D) The zfMC2R (backbone representation) most likely binds the N-terminal MSH-like part of ACTH (translucent surface and amino acids as sticks) similar to MSH in
MC4Rs; however, interplays differently with the extended ligand part that acts antagonistically if supplemented as a separated peptide. Here, several positively
charged amino acid residues are allocated and should interact with the extracellular loops, e.g., negatively charged amino acids (red sticks) in the ECL3.
and oligomers differ and that MC4R/G-protein stoichiometry
depends on this feature, as discussed for several GPCRs (109).
The aforementioned conclusion is generally in accordance with
the suggestion of two different tandemly arranged ligand binding
sites in oligomeric MC4R complexes (88). In relation to this
finding, it must be noted that GPCRs may, in fact, be expressed
as a mixture of monomers and homo-oligomers and that the
different forms interconvert dynamically (110). Consequently,
GPCRs might be expressed in specific monomer/homodimer
ratios at the membrane and in intracellular compartments (111–
113). In such cases, the respective contributions of monomers
and dimers to the cellular signaling output are usually unclear,
which hinders appropriate interpretation of, e.g., dose-response
curves in terms of a dissection between monomer/oligomer
mediated signaling. The potential functional relevance of
oligomeric constellations is also confirmed for the zfMC5R,
whereby receptor oligomerization is hindered by the protein
interaction with zebrafish Mrap2 (114).
The next question to address is how MC4R oligomers should
be constituted from a structural perspective. Based on previously
determined crystal structures of class A GPCR dimers [reviewed
in Audet and Bouvier (73)] and many biophysical studies, several
oligomeric GPCR protomer arrangements have been suggested
(115). Several crystal structures are available, for example, for
the chemokine receptor CXCR4 (116), µ-opioid-receptor [MOR
(117)], κ-opioid receptor [KOR (118)], opsin (119–122), or the
β-adrenergic receptor 1 [β-1AR (123)]. In opsin, KOR, and β-
1AR, the protomer interface is located at TMH1-TMH2 and
helix 8. Interfaces between GPCR protomers at the region from
ICL2 to TMH4 (124–126), TMH4-TMH5 (127), or TMH5-
TMH6 (128–130) were also supported by experimental data
for different GPCRs. For MC4R, a putative protomer-protomer
interface between TMH3-ICL2-TMH4 (Figure 7), respectively,
was recently suggested based on experiments leading to a forced
MC4R monomerization by modification of specific structural
components in this region (72). As other protomer-protomer
interfaces cannot be excluded, we suggest further potential
homo-/heteromeric MC4R dimer packing constellations based
on the afore described information on different GPCRs: (i)
an MC4R homodimer with an interface between TMH3-ICL2-
TMH4, and (ii) an interface at TMH1-TMH2-helix8 (Figure 7).
Such dimer packing constellations in an alternating arrangement
can be also assumed for higher order complexes such as
tetrameric oligomers.
The question to be asked here is whether this structural
information is relevant for receptor function beyond the
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FIGURE 7 | Different putative MC4R homodimer and heteromer arrangements. The MC4R has the capacity to constitute homodimers or homo-oligomers (42–44). In
(A,B), two different homodimeric MC4R constellations are supposed with different interfaces. (A) MC4R homodimer with an interface between parts of TMH4 (or H4),
intracellular loop 2 (ICL2 or I2), and the TMH5 (or H5) based on the determined dimeric crystal structure of CXCR4 (cyan). Such arrangements should also be
assumed for a heterodimeric constellation as reported for MC4R and MC3R (40) (gray, MC4R; green, MC3R). In (B), the MC4R protomers are in contact via the
interface between TMH1-TMH2-H8 based on a determined KOR structure (magenta backbone). Heteromeric MC4R constellations, such as with the GPR7 (47), may
also be arranged in such a constellation. Moreover, in (C) a tetrameric MC4R arrangement is shown, with the supposed interfaces alternating between dimers. (D) An
alternating dimer arrangement for higher complexes is also feasible for tetrameric heteromers.
MC4R/G-protein stoichiometry (109) or the interplay between
two ligand binding sites (88). New developments of potent so-
called homobivalent ligands, differing in the length and nature
of the spacer between two pharmacophore sites, supported
the notion of the functional relevance of receptor dimers
or higher oligomers. An example of a relationship between
structural properties, oligomeric arrangements, and molecular
biology is the recently described MC4R homobivalent agonist
CJL-1-87 with a 20-atom spanning spacer connecting two
“HdFRW” ligand motif pharmacophore moieties (core amino
acids of MSH, Supplementary Figure 4) (39, 40). The unique
pharmacology of this homobivalent ligand with increased
in vitro binding affinity was suggested to enhance in vivo
functional potency and increased ligand residence time has
a crucial impact on the ligand’s effectiveness. This results in
decreased food intake in rodents after fasting and might be
a result of interaction either with MC3R homodimers, MC4R
homodimers, or heterodimers between MC3R and MC4R. Based
on our dimeric homology models (Supplementary Figure 4),
we show that in a putative MC4R homodimer with a
TMH4/5-TMH4/5 interface (Figure 7A), the two ligand moieties
can be located in the orthosteric (MSH) binding sites at
both protomers, whereby a distance of approximately 25
Å between the ligand moieties would be ideal for the
specific linker length as reported. In case of an alternative
TMH1/TMH1-helix 8/helix 8 protomer interface (Figure 7B),
the approximate distance to be bridged by the linker would
be above 55 Å and hence a bivalent ligand molecule would
not bind into both protomers of this dimer. Based on these
rational structural perspectives, the design of appropriate
ligand constructs with specific properties should be refined
and potentially improved in further approaches of directed
ligand design.
Mechanisms and Structural Features
Involved in Signaling Regulation at the
MC4R
The above-described information regarding the MC4R amino
acid sequence, potential MC4R structure, available valuable
insights into ligand binding, and associated receptor regulation
mechanisms such as oligomerization or interaction with other
proteins, lead to the key question of how the signaling process at
the MC4R occurs in detail. Therefore, we summarized available
information in a simplistic scheme (Figure 8).
In brief, signal transduction at the MC4R generally includes:
(a) extracellular binding of ligands such as MSH for signal
induction or in the case of AgRP to inhibit agonist binding
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FIGURE 8 | Signaling regulation and putative interaction with tuning factors at the MC4R. This complex model between MC4R, α-MSH, and Gs visualizes different
steps in signal transduction that are interrelated. Starting from the extracellular site, the ligand binds between the extracellular loops (E1-3) and transmembrane helices
(H1-7). Ligand binding induces structural rearrangements in the transmembrane spanning part. It can be postulated that biased agonism is also associated with
diversely initiated signaling pathways in the transmembrane core (colored arrows). The G-protein can fit into the receptor open crevice at the intracellular site, which is
accessible in consequence to the ligand-induced receptor activation. This ternary complex finally stabilizes an active state conformation of the receptor with a defined
affinity and selectivity for different intracellular effectors. In addition, the melanocortin system can be assisted by the membrane spanning dimeric (131) melanocortin
receptor accessory protein (MRAP2) (132). Homo- or hetero-oligomerization of the MC4R (Figure 7) is a further regulating element in the signaling process (48).
MC4R also directly or indirectly impacts the ion channel Kir 7.1 (21), is influenced by interaction with GRP78 (133), or zinc and sodium ions (52, 89). Based on a recent
study (52), it can be supposed that small drug-like molecules bind into an allosteric binding site between the transmembrane helices under active support of amino
acid residues at N-terminal extension.
and decrease basal signaling activity, (b) signal transduction
through the transmembrane spanning region by movement of
specific helical parts, and (c) to finally enable specific binding
and activation of intracellular transducers/effectors such as G-
proteins, arrestin. These general steps are concerted and are
strongly dependent on structural features.
In detail, at the extracellular site, the ligand binds at
specific determinants between the ECLs and the TMHs (via
complementary recognition motifs, Figures 3, 4), inducing
structural rearrangements in the transmembrane spanning
region, specifically at helices 5, 6, and 7. This leads to a
shift of the receptor structure toward an activity state that is
at an energetically higher predisposition to bind intracellular
signal transducers. Ionic interactions such as with zinc (89) or
sodium (52) may impact the dynamic process of ligand binding
or conformational changes. Moreover, the oligomeric MC4R
arrangement may influence ligand binding properties by the
mutual impact of the interacting protomers, respectively (88). Of
note, it can be postulated that biased signaling of specific MC4R
ligands is associated with diversely initiated signaling pathways
in the transmembrane region, as has been shown for MSH vs.
setmelanotide ligand effects, which induces different selective
favoring pathways (50).
However, after ligand binding and modifications in the
transmembrane region, the G-protein molecule can fit spatially
into a particularly defined receptor crevice at the intracellular site,
which also exposes complementary determinants responsiveness
to certain interacting molecules such as G-proteins or arrestin
receptor selectivity at the intracellular site as suggested for, e.g.,
rhodopsin (134). This ligand/receptor/G-protein (or arrestin)
ternary complex finally stabilizes an active state conformation
of the receptor. As described above, this process can be assisted
or modified by further membrane spanning interaction partners
such as the MC4R itself in homomeric constellations, through
interaction with other GPCRs in heteromers, or proteins such
as MRAP2 (132), or KIR channels (21). It must be noted
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that in consequence of these functionally and structurally
distinguishable levels of signal transduction (Figure 8), the
resulting signal [e.g., (135, 136)] can be specified or tuned at
certain intermediate states, such as during selective ligand, ion,
or G-protein binding. The exact deciphering of hot-spots in the
receptor/ligand interplay, enabling a pathway selective signaling
modulation, poses a challenge. Finally, these general and detailed
insights into MC4R signaling enable a more detailed reflection of
putative pathogenic mechanisms at the protein level.
Naturally Occurring MC4R Mutations in a
Structural-Functional Context
As previously mentioned, inactivating MC4R mutations are
the most frequent monogenic cause of obesity (24). In the
Supplementary Table 1, we summarized reported naturally
occurring MC4R single side-chain amino acid substitutions (stop
mutations, deletions, and double substitutions were excluded)
and mapped their positions on the α-MSH/MC4R/G-protein
ternary complex model (Figure 9) to estimate general and
detailedmolecular features of individual substitutions. Moreover,
we also examined each study for experimental data characterizing
the respective MC4R variant by in vitro experiments to
roughly evaluate functional parameters influenced by these
respective mutations.
One hundred and sixty-five different substitutions at 129
distinct MC4R amino acid positions were collected; hence,
more than one-third of all MC4R residues are exchanged
in obese patients (Supplementary Table 2). First, it must be
emphasized that for 24 of the 165 MC4R variants collected, there
is no functional in vitro data (Supplementary Tables 1, 2,
Supplementary Figure 5). Of specific note, a receptor
function “like wild-type” with either respect to cAMP
accumulation and/or α-MSH binding were characterized in
vitro in 71 of the reported mutations (Supplementary Table 1,
Supplementary Figure 5). In contrast, 92 of the 165 mutants
were reported to cause a decrease in α-MSH binding and/or
cAMP accumulation or cell surface expression (22 mutants
were reported to be contradictory with both like wild-type or
decreased signaling). In conclusion, aside from a huge amount
of reports on pathogenic MC4R variations, this analysis also
shows the huge gap of information that we are still faced with,
particularly concerning the important question: What is the
molecular relationship (e.g., increased, decreased, or selective
signaling pathways) between an identified sequence variation and
a dysfunction in obese patients? This further leads to the question
concerning how to relate an identified MC4R variant causatively
with a certain specific phenotype if the in vitro characterization
does not reveal drastic changes in specific molecular aspects such
as cell surface expression or G-protein activation.
Of note, in addition to the Gs-mediated cAMP signaling
pathway, MC4R has been shown to regulate signaling using
Gi/Go (137), Gq (135), c-Jun N-terminal kinase (JNK) (138),
ERK1/2 signaling (139), and cAMP-independent activation of
the ion channel Kir 7.1 (21). Altogether, characterizing identified
naturally-occurring MC4R variants systematically with respect
to different signaling pathways would be of interest and may
support the identification of the exact pathogenic mechanism
underlying the patient-phenotype, as shown recently (19, 50).
The afore described information makes it reasonable to postulate
that contemporary approaches of MC4R mutant investigation
should take a more completed set of signaling pathways
under consideration, especially for mutations that have not
shown any effects in Gs-mediated signaling (highlighted in
Supplementary Table 1 with “=”). Several mutations have been
identified to induce biased preferred signaling in regards to
ERK1/2 and Gs-mediated cAMP signaling (139) (marked with
“∗” in Supplementary Table 1).
Second, inactivation of a functional ternary complex
constituted by ligand/receptor/intracellular signal transducer
can occur at different levels but generally, result in the
“inactivation” of the complex unit. Receptor mutations can
impair protein function at the transcription, translation, folding,
ligand binding, or downstream signaling level (140). Impaired
translation and protein misfolding can result in a reduced
number of receptors presented at the cell surface. Changes of
signaling may be related to modifications in the ligand binding
properties or in the MC4R/G-protein contact interface. Based
on our combined mutant collection and three-dimensional
mapping of naturally-occurring MC4R mutations, we are able
to provide an analysis of substitutions that either modulate (i)
ligand binding, (ii) signal transduction in the transmembrane
domain, or influence the (iii) receptor/G-protein interplay.
In principle, the overall distribution of all reported naturally
occurring substitutions is spread over the entire receptor
(Figure 9A, Supplementary Table 1). To analyze the reported
MC4R variants in regard to their respective structural-functional
relationships, we here describe several examples related to either
ligand binding, G-protein recognition, or located at well-known
micro-switches or micro-domains (141) in the helical bundle
involved in signal transduction through the membrane.
The Ligand Binding Region
Interestingly, 21 naturally occurring single side-chain
substitutions in the N-terminal domain at 14 different positions
show predominantly no impact on ligand binding or cAMP
signaling (Supplementary Table 1). This high ratio of reported
naturally-occurring substitutions without a significant change in
receptor/G-protein coupling suggests that the N-terminus may
not contribute significantly to α-MSH binding or Gs-mediated
signaling. Therefore, these variants may impact further receptor
signaling pathways or functions, which should be investigated in
extended experimental studies.
However, the putative binding sites of MC4R ligands were
described recently in detail (50, 52) and in the sections above
(Figures 3, 4).We extracted the following amino acid positions of
reported pathogenic mutations as located in the sensitive region
responsive for binding contacts toMC4R ligands: G32, D37, I125,
D126, S191, I194, F261, and F280 (Figure 9B). Mutations at these
positions may directly prevent or modulate appropriate ligand
binding, which is the case for both agonistic and antagonistic
ligands. This might be due to local structural changes in the
ligand entrance environment of the receptor, thereby preventing
a spatial “fit-in” of the ligand. It can also cause direct changes
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FIGURE 9 | Structural mapping of pathogenic single side chain substitutions in MC4R. (A) Positions of naturally-occurring side chain substitutions
(Supplementary Table 1) are highlighted on a putative active state MC4R model in interaction with α-MSH and G-protein. This structural mapping enables a detailed
estimation of individual molecular mechanisms for each mutation by evaluation of the wild-type amino acid function. The ligand and the heterotrimeric G-protein
(colors: α-subunit, chocolate: β-subunit, wheat; γ-subunit green) are shown as surfaces; the receptor is presented as a backbone ribbon (gray). Residues associated
with pathogenic substitutions are highlighted (sticks), whereby the color magenta indicates an experimentally proven reduction in signaling and the color blue a
reported signaling property that corresponds to wild-type (“like wild-type,” Supplementary Table 1) (no functional molecular data reported so far, white). (B) This
figure shows α-MSH in interaction with MC4R as suggested by our docking studies (Figure 3) and highlights exclusively those wild-type amino acid residues of
reported pathogenic substitutions that are in close proximity or in direct interacting contact to α-MSH. In conclusion, these residues are potentially involved in ligand
binding and any side chain variation may lead to a modified ligand binding capacity. Potential hydrogen bonds between α-MSH and MC4R are shown as dashed lines
(black). (C) Similar to (B), also the detailed MC4R/G-protein interface can be analyzed on the potential participation of wild-type residues that might be involved in
G-protein binding. Indeed, the model suggests that several residues are in direct interaction distance to the α-subunit of Gs, or, e.g., H76 in close proximity to the
β-subunit. In conclusion, pathogenic mutations at these positions can be suggested to modify the MC4R/Gs interface, which, in conclusion, leads to a reduced
signaling capacity for the respective pathway.
within the ligand binding pocket corresponding to different
structural/chemical interaction patterns between the receptor
and the ligand as suggested for the wild-type MC4R. This
concerns, in particular, main interactions such as those observed,
e.g., with the MC4R residue D126 (substitution D-Y) or for
mutants at F261 (substitution F-S) (see Supplementary Table 1).
The Membrane Spanning Region
Our structural mapping of pathogenic mutations highlights
a clustering of variations at the TMH1/2/7 interface in the
transmembrane region. These include P299H, I301T, A303T,
R305W/S in TMH7; E61K, N62S in TMH1, and A87D and
D90N in TMH2. Notably, in TMH1, signal downregulating
substitutions were identified in an extended amino acid
stretch from L54 to N62. Similarly, several mutations in
TMH2 between A87–N97 are clustered, suggesting that the
TMH1-TMH2 interface is of particularly high importance for
receptor-misfolding and/or -mediated signal transduction. This
assumption is supported by the D90N2.50 mutation that has
been identified in several independent studies of obese cohorts
(42, 142–144). The conserved wild-type residue D90 is suggested
to be essential for water-related activation by allosteric sodium
binding (45, 79). These examples of pathogenic mutants in the
transmembrane region are significant because they are located in
structural micro-domains involved either in keeping the receptor
in a structural conformation that is predisposed to become
activated by agonistic ligands, or they are at positions (e.g., in
TMH7) important for stabilizing the active state conformation
after ligand interaction. In any scenario, the interruption of either
hydrophilic or hydrophobic interactions in this area leads to
a receptor state that is unable to become (fully) activated by
ligand action.
The G-Protein Binding Site
Comparable to the disturbed ligand recognition, several
pathogenic mutations can be attributed directly or indirectly
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to negatively modulate the G-protein/receptor interplay. For
example, five of eight residues of the MC4R ICL1 have been
reported with pathogenic effects (Supplementary Table 2),
definitively indicating the high impact of this intracellular loop
for MC4R functions. Our complex homology model (Figure 9C)
supports a potential interaction between ICL1 and the Gβ
subunit of Gs (via hydrogen bonding from the ICL1 amino acids
H76 and K73). In accordance with the occurrence of pathogenic
MC4R variations in this receptor part and our ternary complex
model, the recently published structure of a class B GPCR
(GLP1R) as a complex with a trimeric Gs-protein has shown
detailed structural information regarding an ICL1-Gβ interplay
(145). This is further supported by experimental findings at the
µ-opioid receptor (MOR), whereby initial interactions between
the G-protein and ICL1 may be involved in G-protein coupling
specificity (146).
Generally, the ICL2 and ICL3 of GPCRs are both well-
known to interact with the Gα subunit of Gs (54, 147, 148),
hence mutations in this region are expected for most GPCRs
to directly affect G-protein activation. Based on our MC4R
models, the ICL2 consists of 13 residues, of which six have
been reported to be a pathogenic mutation. Three of these
mutations have been shown experimentally to reduce cAMP
signaling (A154D, Y157S, M161T) (Supplementary Table 2). In
remarkable contrast, substitution H158R has been reported to
result in a 6-fold increased basal activity, which characterizes this
mutation as a constitutively activating mutation (CAM) (149). In
addition, seven pathogenic MC4R mutations at six positions are
located in the ICL3; however, only two of these six mutations
(Figure 9C) were already characterized as reduced in Gs-
mediated signaling (I266T, G238D) (Supplementary Table 1),
indicating the need of extended functional characterization
to evaluate the causality between these variants and patient
phenotypes. Collectively, these mutations and functional insights
highlight all three intracellular loops as important for G-protein
coupling and activation. As described above, the ICL2 and
ICL3 of the MC4R share a high abundance of pathogenic
substitutions with low or no impact on Gs-mediated cAMP
signaling, which predestinates these structural components as
potentially important for other signaling pathways mediated by,
e.g., Gq-protein.
CONCLUSIONS
Altogether, the present study provides an analysis of ligand
interactions and pathogenic variations using an MC4R model to
gain detailed insights into the mode of action and the structural
and functional relationships of the MC4R. This included
putative 3D conformations and complexes, and associated
functional aspects such as details of ligand binding or oligomeric
constellations. Of importance for MC4R research are advanced
insights into questions regarding biased signaling, signaling
modulation by interacting partners or MC4R modulation by
designed ligands, including linear or cyclic peptide ligands,
synthetic small molecules, or bivalent ligands. MC4R-related
research with a primary focus on pharmaceutical, structural, and
biochemical aspects is vital, with the potential to study many
interesting aspects of class A GPCRs at this receptor.
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